Literature DB >> 17183049

The optimum reperfusion pathway for ST elevation acute myocardial infarction: development of a decision framework.

J Kendall1.   

Abstract

There is currently much debate about the relative roles of pharmacological reperfusion (ie, thrombolysis) and mechanical reperfusion (ie, primary percutaneous coronary intervention (PPCI) in the management of patients with acute ST segment elevation acute myocardial infarction (STEMI). Whilst the scientific debate is reaching some resolution in terms of appropriate interpretation of the evidence base, there are still significant resource issues within the UK that limit our ability to implement gold standard reperfusion therapy. Current evidence supports the use of one or other strategy in certain situations depending on various patient-related and logistical factors. This paper reviews the literature and builds the case for developing a strategic approach which includes both mechanical and pharmacological interventions, proposing that these are not mutually exclusive-indeed, that an approach which excludes one of these interventions will not be to the benefit of all patients. There is also a discussion of the role of rescue PPCI, facilitated PPCI and early post thrombolysis angiography in the management of STEMI. Cardiac networks throughout the UK are developing strategies to improve access to these interventions and this paper offers advice on the logical selection of interventions for reperfusion in the context of a clinical decision framework that is evidence-based, pragmatic and develops through a series of scenarios with increasing availability of resources. Four sequential scenarios are presented: the first to set the scene is largely consigned to history; the last, as of yet, is not robustly achievable within the UK, but represents the "optimum reperfusion pathway", to which most cardiac networks are striving. Most of us currently find ourselves in a period of change between the two and will relate to either scenario two or three.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17183049      PMCID: PMC2658158          DOI: 10.1136/emj.2006.042952

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  18 in total

1.  Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis.

Authors:  L J Morrison; P R Verbeek; A C McDonald; B V Sawadsky; D J Cook
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

2.  ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty).

Authors:  S C Smith; J T Dove; A K Jacobs; J W Kennedy; D Kereiakes; M J Kern; R E Kuntz; J J Popma; H V Schaff; D O Williams; R J Gibbons; J P Alpert; K A Eagle; D P Faxon; V Fuster; T J Gardner; G Gregoratos; R O Russell; S C Smith
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

3.  Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?

Authors:  Brahmajee K Nallamothu; Eric R Bates
Journal:  Am J Cardiol       Date:  2003-10-01       Impact factor: 2.778

4.  Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.

Authors:  Philippe Gabriel Steg; Eric Bonnefoy; Sylvie Chabaud; Frédéric Lapostolle; Pierre-Yves Dubien; Pascal Cristofini; Alain Leizorovicz; Paul Touboul
Journal:  Circulation       Date:  2003-11-17       Impact factor: 29.690

5.  Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy.

Authors:  D J Magid; B N Calonge; J S Rumsfeld; J G Canto; P D Frederick; N R Every; H V Barron
Journal:  JAMA       Date:  2000-12-27       Impact factor: 56.272

6.  Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study.

Authors:  Eric Bonnefoy; Frédéric Lapostolle; Alain Leizorovicz; Gabriel Steg; Eugène P McFadden; Pierre Yves Dubien; Simon Cattan; Eric Boullenger; Jacques Machecourt; Jean-Micel Lacroute; Jean Cassagnes; François Dissait; Paul Touboul
Journal:  Lancet       Date:  2002-09-14       Impact factor: 79.321

7.  A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial.

Authors:  Andrew G C Sutton; Philip G Campbell; Richard Graham; Dallas J A Price; Janine C Gray; Ever D Grech; James A Hall; Alun A Harcombe; Robert A Wright; Roger H Smith; Jerry J Murphy; Ananthaiah Shyam-Sundar; Michael J Stewart; Adrian Davies; Nicholas J Linker; Mark A de Belder
Journal:  J Am Coll Cardiol       Date:  2004-07-21       Impact factor: 24.094

8.  Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.

Authors:  Frans Van de Werf; Diego Ardissino; Amadeo Betriu; Dennis V Cokkinos; Erling Falk; Keith A A Fox; Desmond Julian; Maria Lengyel; Franz-Josef Neumann; Witold Ruzyllo; Christian Thygesen; S Richard Underwood; Alec Vahanian; Freek W A Verheugt; William Wijns
Journal:  Eur Heart J       Date:  2003-01       Impact factor: 29.983

9.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).

Authors:  Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs
Journal:  Circulation       Date:  2004-08-03       Impact factor: 29.690

Review 10.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

View more
  2 in total

1.  Do we need new clinical standards in management of acute myocardial infarction?

Authors:  Matthew W Cooke
Journal:  Emerg Med J       Date:  2007-05       Impact factor: 2.740

2.  Treatment costs of acute myocardial infarction in the Netherlands.

Authors:  R R Soekhlal; L T Burgers; W K Redekop; S S Tan
Journal:  Neth Heart J       Date:  2013-05       Impact factor: 2.380

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.